SanBio Inc. recently received approval from the U.S. Food and Drug Administration to test a regenerative cell therapy on patients who have become disabled as a result of ischemic stroke, or strokes caused by blocked blood vessels in the brain. This is the only clinical trial in the United States currently testing the regenerative potential of cell therapy in the brain, according to company officials.
No comments:
Post a Comment